Co-Chairs:                                               Faculty:          

Thomas Lynch, Jr, MD                                Robert Pirker, MD

Yale School of Medicine                              Medical University of Vienna

New Haven, Connecticut                             Vienna, Austia

Alberto Sobrero, MD                                  David Ryan, MD

San Martino Hospital                                  Massachusetts General Hospital

Genova, Italy                                             Boston, Massachusetts

Is individualized therapy for common solid tumors ready for prime time?

Thomas Lynch, Jr, MD

Pattern of practice question: Targeting EGFR in metastatic colorectal cancer

How should we integrate EGFR inhibitors into first-line therapy for metastatic colorectal cancer?

David Ryan, MD

Interactive clinical case: Metastatic colorectal cancer

Alberto Sobrero, MD

Pattern of practice question: Targeting EGFR in NSCLC

Contemporary strategies for incorporating anti-EGFR therapies in advanced NSCLC 

Robert Pirker, MD

Interactive clinical case: Advanced NSCLC

Thomas Lynch, Jr, MD

Individualized therapy:  Where do we go from here?

Alberto Sobrero, MD

Both lung cancer and colorectal cancer have a large impact, with 215,020 new cases of lung cancer and 161,840 deaths estimated in 2008, and an estimated 148,810 new cases and 49,960 deaths from colorectal cancer in 2008. Despite the many advances made in the fields of NSCLC and colorectal cancer, current treatment options are mostly unsuccessful for patients who relapse after initial treatment. 

The fields of NSCLC and colorectal cancer are constantly being updated, especially with regard to the optimal application of EGFR inhibitors, and oncologists in both academic and community practice settings need easily accessible, one-stop resources where they can review and validate current standards and practice guidelines in order to optimize and individualize patient care. PRIME Oncology will meet this educational need through a satellite symposium titled Individualizing Targeted Therapy for Lung and Colorectal Cancers. The symposium will provide expert analysis of optimal approaches to integrating EGFR inhibitors into clinical practice. 

Upon completion of this educational activity, participants should be able to:

• Identify potential methods for predicting clinical response to epidermal growth factor receptor (EGFR) targeted agents in colorectal cancer and non-small cell lung cancer (NSCLC)
• Review recent clinical data regarding the use of EGFR antibodies as first-line therapy for metastatic colorectal cancer and advanced NSCLC
• Identify the potential role of combining radiation with EGFR inhibitors in the management of advanced NSCLC
• Define strategies for the integration of EGFR inhibitors into clinical practice
• Describe markers that may allow oncologists to individualize therapy for metastatic colorectal cancer and advanced NSCLC